As 2016 ends, we are looking forward to an exciting New Year at the Medicines Discovery Catapult (MDC).
Chris was appointed CEO of the new Medicines Discovery Catapult in 2016. He has over 25 years international Executive and Board experience across multiple areas of Medicines Discovery.
He began his career in discovery biology at Glaxo, and continued at Glaxo Wellcome and GSK, delivering transformational change across research by implementing specialist automation and informatics systems. He then moved into biotech as Chief Operating Officer of MerLion Pharmaceuticals in Singapore.